Timex Group promoter to sell 4.47% stake via OFS at ₹275 per share

Timex Group Luxury Watches BV will sell a 4.47 percent stake in Timex Group India via OFS on December 29 and 30, with Kotak Securities as broker and a floor price of ₹275 per share.

Timex Group Luxury Watches BV will sell a 4.47 percent stake in Timex Group India via OFS on December 29 and 30, with Kotak Securities as broker and a floor price of ₹275 per share.

Vikran Engineering Ltd accepted awards from MP Urja Vikas Nigam Ltd to set up 45.75 MW solar projects in Vidisha under PM-KUSUM, selling power to MPPMCL for 25 years. Shares of Vikran Engineering Ltd ended lower on Friday, December 26,…

IFSCA chairman K Rajaraman said the GIFT City bond market is primarily institutional, with Indian corporates raising offshore debt through NSE IX and India INX. While resident retail investors have limited access, regulators have strengthened disclosure and credit rating norms…

Titan’s move into lab-grown diamonds marks a cautious but strategic diversification, with the Tata Group company positioning the ‘beYon’ brand as an affordable, lifestyle-led offering for women. While the near-term revenue impact is expected to be modest, the entry of…

The Great Eastern Shipping Company Ltd will sell its gas carrier Jag Vishnu and Kamsarmax Jag Aarati, and acquire two second-hand vessels, aiming to optimise its fleet to 39 ships by FY26.

Coal India Ltd appoints B Sairam as CEO, consolidating leadership. Sairam, with over 30 years in coal, previously led Northern Coalfields Ltd and Central Coalfields Ltd.

Post Content

Benchmark indices ended the week with modest gains, snapping a three-week losing streak, while Friday saw Nifty slip below 26,050, dragged lower by IT and auto shares, with Sensex down 367 points.

Devang Mehta, Deputy Managing Director and Chief Investment Officer–Equity (NDPMS) at Spark Private Wealth Management, said the investment case for railway and PSU companies has moved beyond short-term pre-budget seasonality. He stated that these stocks are now increasingly driven by…

Sun Pharmaceutical Industries targets mid- to high-single digit topline growth in FY26, focusing on innovative medicines and increased R&D investment.